Show Filters

Searches all publications.

Search Fulltext



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-06-25
    E.g., 2018-06-25


19310 items
5:25 PM, Jun 15, 2018  |  BioCentury | Product Development

NSCLC disrupted

This year’s ASCO made clear that PD-1 inhibitors have supplanted chemotherapy as standard of care in first-line metastatic NSCLC. The unanticipated consequence is the knock-on effects for companies with studies under way in both first-...
5:18 PM, Jun 15, 2018  |  BioCentury | Finance

Rejuvenating aging

Anti-aging company Juvenescence Ltd. is hoping to bring a total of 10 candidates from its portfolio companies and academic partnerships into the clinic over the next two years with its recent $50 million series A...
3:21 PM, Jun 15, 2018  |  BioCentury | Regulation

Safer harbor

FDA guidance released on June 12 clears up regulatory ambiguities that have restricted drug and device company communications with payers, physicians and patients. A primary goal is to make it easier to base payments on...
11:03 PM, Jun 13, 2018  |  BioCentury | Finance

Gene therapies in Sync

With the launch of a pair of new start-ups, Syncona Ltd. (LSE:SYNC) has invested in a CNS play and a new ophthalmic approach, bringing the U.K. firm’s gene therapy portfolio to five. Syncona invested $23 million...
9:27 AM, Jun 12, 2018  |  BioCentury | Emerging Company Profile

A Cancer Target Revolution

Revolution Medicines Inc. is developing inhibitors that target non-catalytic sites on proteins to block cell signaling pathways, such as Ras, that drive cancer cell proliferation. The company’s platform combines synthetic and medicinal chemistry, biochemistry, and structural...
7:17 PM, Jun 08, 2018  |  BioCentury | Finance

ASCO ascent

Kinase inhibitor company Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) and cancer assay developer Genomic Health Inc. (NASDAQ:GHDX) each hit all-time highs in the wake of data readouts at the American Society of Clinical Oncology meeting in Chicago. Deciphera...
7:02 PM, Jun 08, 2018  |  BioCentury | Product Development

POC for cytokines

A body of clinical evidence is emerging that two different approaches to immune-stimulating cytokine therapies could increase efficacy of PD-1 inhibitors in both hot and cold tumors. Oncologists who spoke to BioCentury said, taken together, data...
6:43 PM, Jun 08, 2018  |  BioCentury | Product Development

Past not prologue

Loxo Oncology Inc.’s two-year streak of stunning data at ASCO appears to be the result of good decisions on the back of a healthy dose of luck. But it will be a tall order to...
8:32 AM, Jun 08, 2018  |  BioCentury | Finance

Pfizer plugs back in

While Pfizer Inc. (NYSE:PFE) retreated from neuroscience R&D in January, the pharma hasn’t cut the cord yet. Ramped up allocations to neuroscience out of its latest $600 million venture investment give Pfizer the ability to...
7:58 AM, Jun 08, 2018  |  BioCentury | Finance

Nimbus looks inward

Nimbus plans to use a $65 million financing it raised on Tuesday to take programs deeper in development, refining its founding strategy of partnering its compounds early on. Existing investor Atlas Venture led the round,...